Drug Repurposing for Rare Diseases 2020 Conference

Findacure's Drug Repurposing for Rare Diseases Conference is returning for its seventh consecutive year!  Developing drugs for rare diseases is challenging, both due to limited knowledge and small patient populations. Where treatments do exist, they often come with high price tags which healthcare providers struggle to pay for.

Dates Monday, February 24, 2020 - Download as vCalendar
Event Times: 10:00 to 18:00
Venue America Square Conference Centre, 17 America Square, EC3N 2LB
Contact Name Mary Rose Roberts
Email maryrose@findacure.org.uk
Contact Phone 01223 222767
Website Event website

Event details:

Our annual conference discusses the role that drug repurposing can play in lowering the cost and accelerating the development of rare disease treatments. Held in celebration of Rare Disease Day, our event will unite the rare disease community to showcase innovative and groundbreaking drug repurposing projects that can bring real change to those living with rare diseases.

The conference, taking place on 24th February at the America Square Conference Centre, is open to anyone with an interest in rare diseases and lunch and refreshments will be provided. The day will include a diverse selection of invited speakers, a panel discussion, awards for the winners of our 2019 'Student Voice' essay competition, and a lightning talk session where delegates can propose their own five-minute talks.

Tickets are available on Eventbrite, with free tickets are available for carers of paid and registered delegates.

For any questions, please contact maryrose@findacure.org.uk.

Sign up NOW!

Sponsorship and exhibition opportunities

We offer a variety of sponsorship and exhibition opportunties at our conference. If you would like to find out more, please contact maryrose@findacure.org.uk.

Findacure is a UK charity working towards a world in which all rare diseases have treatments made with patients in mind. We empower patient advocates through a range of training programmes and introduce them to all the multiple stakeholders, including patient groups, researchers and pharma, to achieve this vision.